CO5200789A1 - Derivados i quinolin-4-il - Google Patents

Derivados i quinolin-4-il

Info

Publication number
CO5200789A1
CO5200789A1 CO00073351A CO00073351A CO5200789A1 CO 5200789 A1 CO5200789 A1 CO 5200789A1 CO 00073351 A CO00073351 A CO 00073351A CO 00073351 A CO00073351 A CO 00073351A CO 5200789 A1 CO5200789 A1 CO 5200789A1
Authority
CO
Colombia
Prior art keywords
lower alkyl
phenyl
amino
hydrogen
aminobutanol
Prior art date
Application number
CO00073351A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5200789A1 publication Critical patent/CO5200789A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Compuestos de la fórmula<EMI FILE="00073351_1" ID="1" IMF=JPEG >en dondeR1 es hidrógeno, alquilo inferior, alcoxilo inferior, hidroxilo, arnino, nitro, ciano, alquil-amino inferior, di-alquil-amino inferior o halógeno; R2 es fenilo, opcionalmente sustituido por alquilo inferior,alcoxilo inferior, halógeno, trifluorometilo, amino,alquil-amino inferior o di-alquil-amino inferior,2,3-dihidro-benzofuran-5-ilo, croman-6-ilo, naftalen-2-ilo, indan-5-ilo, alquilen-fenilo inferior, 5,6,7,8 tetrahidro - naftalenilo, 2,3-dihidro - isoindol-2-ilo, 1,2, 3, 4-tetrahidro-naftalenilo, benzofuran-2-ilo,benzo [b] tiofen-2-ilo, alquil-fenilo inferior, 3,4-dihidro-1H-isoquinolin-2-ilo o tiofen-3-ilo;R3 y R4 son, independientemente uno de otro hidrógeno o alquilo inferior;R3 es hidrógeno, alquilo inferior, -CH2OH o -CH2NR6R7;R6 y R7 son, independientemente uno de otro, hidrógeno, alquilo inferior -(CH2)n-fenilo, cicloalquilo, -(CH2)m-morfolinilo o forman junto con el átomo de N un anillo saturado con 4-6 átomos de C; n es 0-3;m es 2- 3;X es -NR8- u -O-; oX y R5 son, conjuntamente, ANDgt;N(CH2)2-; oX y R3 son, conjuntamente, ANDgt;N(CH2)3-; yR8 es hidrógeno o alquilo inferior;y sus sales de adición de ácido farmacéuticamente aceptables,con la excepción de los compuestos siguientes(6-cloro-2-fenil-4-quinolinil)-(+)-2-aminobutanol;(6-metil-2-fenil-4-quinolinil)-(+)-2-aminobutanol;(6-metoxi-2-fenil-4-quinolinil)-(+)-2-aminobutanol; y(8-metoxi-2-fenil-4-quinolinil)-(+)-2-aminobutanol.
CO00073351A 1999-10-01 2000-09-27 Derivados i quinolin-4-il CO5200789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99119539 1999-10-01

Publications (1)

Publication Number Publication Date
CO5200789A1 true CO5200789A1 (es) 2002-09-27

Family

ID=8239107

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00073351A CO5200789A1 (es) 1999-10-01 2000-09-27 Derivados i quinolin-4-il

Country Status (26)

Country Link
US (1) US6440995B1 (es)
JP (1) JP3523174B2 (es)
KR (1) KR100398561B1 (es)
CN (1) CN1181059C (es)
AR (1) AR025882A1 (es)
AT (1) ATE281436T1 (es)
AU (1) AU774363B2 (es)
BR (1) BR0004548A (es)
CA (1) CA2321324A1 (es)
CO (1) CO5200789A1 (es)
CZ (1) CZ20003575A3 (es)
DE (1) DE60015471T2 (es)
ES (1) ES2230017T3 (es)
HR (1) HRP20000639A2 (es)
HU (1) HUP0003861A3 (es)
ID (1) ID27525A (es)
IL (1) IL138777A0 (es)
MA (1) MA26752A1 (es)
NO (1) NO20004892L (es)
NZ (1) NZ507141A (es)
PE (1) PE20010648A1 (es)
PL (1) PL342876A1 (es)
PT (1) PT1088818E (es)
SG (1) SG164268A1 (es)
TR (1) TR200002831A3 (es)
ZA (1) ZA200005239B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831087B2 (en) * 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
RU2285693C2 (ru) * 2002-02-13 2006-10-20 Ф.Хоффманн-Ля Рош Аг Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv
US7648984B2 (en) * 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
EP2573080A1 (en) * 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9840500B2 (en) * 2014-06-16 2017-12-12 Fundación Para La Investigación Médica Aplicada Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
KR20170074178A (ko) * 2015-12-21 2017-06-29 제이엔씨 주식회사 중합성 액정 화합물, 조성물, 그 액정 중합막류 및 이들의 용도
CN105646462B (zh) * 2016-01-19 2019-04-05 河南大学 芸香宁碱衍生物、其制备方法及应用
EP3619210A4 (en) 2017-05-01 2020-12-02 Sanford Burnham Prebys Medical Discovery Institute LOW MOLECULAR PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE440008C (de) 1924-03-29 1927-05-04 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Chinolinderivaten
US4560692A (en) 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5441963A (en) 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
HUP0003861A3 (en) 2002-09-30
CA2321324A1 (en) 2001-04-01
NO20004892L (no) 2001-04-02
NO20004892D0 (no) 2000-09-29
NZ507141A (en) 2002-05-31
ATE281436T1 (de) 2004-11-15
BR0004548A (pt) 2001-05-29
AU6132400A (en) 2001-04-05
DE60015471D1 (de) 2004-12-09
ID27525A (id) 2001-04-12
TR200002831A2 (tr) 2001-04-20
JP3523174B2 (ja) 2004-04-26
HU0003861D0 (en) 2000-12-28
DE60015471T2 (de) 2005-10-27
JP2001097952A (ja) 2001-04-10
MA26752A1 (fr) 2004-12-20
IL138777A0 (en) 2001-10-31
HRP20000639A2 (en) 2001-06-30
ES2230017T3 (es) 2005-05-01
US6440995B1 (en) 2002-08-27
CZ20003575A3 (cs) 2001-11-14
ZA200005239B (en) 2001-04-16
AU774363B2 (en) 2004-06-24
HUP0003861A2 (hu) 2001-10-28
KR20010050738A (ko) 2001-06-15
CN1290698A (zh) 2001-04-11
PT1088818E (pt) 2005-03-31
CN1181059C (zh) 2004-12-22
AR025882A1 (es) 2002-12-18
KR100398561B1 (ko) 2003-09-19
TR200002831A3 (tr) 2001-04-20
PE20010648A1 (es) 2001-06-13
PL342876A1 (en) 2001-04-09
SG164268A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
CO5251440A1 (es) Derivados de heterociclil-fenil-oxazolidin-tiofencarboxamida, su procedimiento de obtencion y medicamentos que los contienen
CO5060482A1 (es) Derivados terapeuticos de biarilo
CO4990936A1 (es) Derivados de n-aroilfenilalanina
HRP950482B1 (en) SYNTHESIS OF 3-(4-(2-AMINOETOXY)BENZOYL)-ARYL-6-HYDROXYBENZO(b)THIOPHENE
ATE470662T1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
ES2167371T3 (es) Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos.
CO4990955A1 (es) Derivados de n-alcanoilofenilalanina
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
CO5080780A1 (es) Derivado de amida y antagonista de nociceptina
AR040694A1 (es) Derivados de benzodioxol como antagonistas de los receptores cb1
CO5251464A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina
DE69613240T2 (de) N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
CO4970780A1 (es) Nuevos compuestos heterociclicos de piridazina
CO5200789A1 (es) Derivados i quinolin-4-il
CO5690577A2 (es) Derivados de imidazoquinolina como ligandos receptores de adenosina a3
YU47728B (sh) Azaoksindol derivati
ES2179005T3 (es) Compuesto de cromeno.
CO5130006A1 (es) Compuestos de pirazina
ES456610A1 (es) Procedimiento para preparar derivados de sulfonamida.
MX9200589A (es) Imidazopiridinas antagonistas de fap/h1. imidazopiridinas antagonistas de fap/h1.
KR920006350A (ko) 3-아릴-4(3h)퀴나졸리논 cck 길항물질 및 그의 약학 조성물
DE3575140D1 (de) Dreizyklische oxindole als antientzuendungsmittel.
AR045326A1 (es) Derivados de aminoquinolina y su uso como ligandos a3 de adenosina
DE60130766D1 (de) Serotoninwiederaufnahme-inhibitoren

Legal Events

Date Code Title Description
FA Application withdrawn